๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Refractory/Relapse Neuroblastoma

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate Study in Children and Adolescents of 177Lu-DOTATATE (Lutatheraยฎ) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site๐Ÿ“ Boadilla del Monte Fundaciรณn de investigaciรณn HM ยท Tests: Olaparib; 177Lu-DOTATATE Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma NCT07027748Phase 12 sites๐Ÿ“ Boston๐Ÿ“ Boston Steven DuBois, MD ยท Tests: Naxitamab, Irinotecan, Temozolomide, Sargramostim granulocyte-macrophage colony stimulating factor Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug Vedotin TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma NCT05562024Phase 12 sites๐Ÿ“ Jinan๐Ÿ“ Tianjin PersonGen BioTherapeutics (Suzhou) Co., Ltd. ยท Tests: T cell injection targeting B7-H3 chimeric antigen receptor Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma NCT07375563Phase 31 site๐Ÿ“ Moscow Federal Research Institute of Pediatric Hematology, Oncologโ€ฆ ยท Tests: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell proโ€ฆ Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma NCT07767630EARLY Phase 11 site๐Ÿ“ Chengdu Sichuan University ยท Tests: [211At]MABG Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma NCT06013618Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen University Cancer Center ยท Tests: Naxitamab monotherapy, GM-CSF, Irinotecan, Temozolomide, Naxitamab in combination therapy Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors NCT05608148Phase 11 site๐Ÿ“ Fukuoka Kyushu University ยท Tests: Biological, Biological, Biological, Biological NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial NCT06450041Phase 213 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Aurora New Approaches to Neuroblastoma Therapy Consortium ยท Tests: Universal Donor (UD) TGFฮฒi NK Cells, Temozolomide, Irinotecan, Dinutuximab, GM-CSF Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma NCT07067346EARLY Phase 12 sites๐Ÿ“ Chengdu๐Ÿ“ Chengdu Sichuan University ยท Tests: IR-101 Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors NCT06625190Phase 1, Phase 21 site๐Ÿ“ Gainesville University of Florida ยท Tests: Miltenyi CliniMACS Prodigy ยฎ system, Zoledronic acid Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma NCT05400603Phase 11 site๐Ÿ“ Atlanta Emory University ยท Tests: Ex Vivo Expanded Allogeneic ฮณฮด T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas NCT06465199Phase 1, Phase 214 sites๐Ÿ“ Birmingham๐Ÿ“ Little Rock๐Ÿ“ Hartford Milton S. Hershey Medical Center ยท Tests: Eflornithine (DFMO), AMXT 1501 Dicaprate Quadruple Immunotherapy for Neuroblastoma NCT05754684Phase 21 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: Natural killer cell, Dinutuximab beta, Interleukin-2, Granulocyte-Macrophage Colony-Stimulating Factor, Spironolactone Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma NCT03721068Phase 12 sites๐Ÿ“ Atlanta๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease NCT05272371Phase 11 site๐Ÿ“ Krakow Jagiellonian University ยท Tests: Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy) B7-H3.CD28Z.CART in Solid Tumors NCT07358260Phase 11 site๐Ÿ“ Boston Robbie Majzner ยท Tests: B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. NCT06836505Phase 1, Phase 23 sites๐Ÿ“ Guangzhou๐Ÿ“ Dongguan๐Ÿ“ Shanghai Sun Yat-Sen University Cancer Center ยท Tests: CART therapy NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma NCT07211737Phase 11 site๐Ÿ“ Houston Baylor College of Medicine ยท Tests: i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells, i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells, i15.NKG2D.zeta NK celโ€ฆ A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma NCT07085338Phase 25 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Ann Arbor St. Jude Children's Research Hospital ยท Tests: Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma NCT06540963Phase 212 sites๐Ÿ“ Little Rock๐Ÿ“ Hartford๐Ÿ“ Miami Giselle Sholler ยท Tests: Tipifarnib, Naxitamab Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma NCT06803875Phase 1, Phase 22 sites๐Ÿ“ Boston๐Ÿ“ Boston Roberto Chiarle ยท Tests: Autologous hALK.CAR T cells PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors NCT06721689Phase 1, Phase 27 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Boston Theodore Laetsch ยท Tests: PEEL-224, Vincristine, Temozolomide (TMZ) Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors NCT06500819Phase 11 site๐Ÿ“ Palo Alto Stanford University ยท Tests: B7-H3CART Dose (Intravenous) Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children NCT07318831Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma NCT04903899Phase 25 sites๐Ÿ“ Copenhagen๐Ÿ“ Vilnius๐Ÿ“ Utrecht Jakob Stenman ยท Tests: 177Lu-DOTATATE Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) NCT07172958Phase 12 sites๐Ÿ“ Washington D.C.๐Ÿ“ Washington D.C. Children's National Research Institute ยท Tests: Selective Antigen Specific dTฮฒRII-expressing T cells combined with B7-H3 CAR T cells Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma NCT06995872Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: rhIL-15, Dinituximab, Temozolomide, Irinotecan Hydrochloride Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors NCT06541262Phase 1, Phase 224 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Oakland Milton S. Hershey Medical Center ยท Tests: Silmitasertib, Irinotecan, Temozolomide, Vincristine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy